Nature Communications (Mar 2024)
Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
- Lenka Kasikova,
- Jana Rakova,
- Michal Hensler,
- Tereza Lanickova,
- Jana Tomankova,
- Josef Pasulka,
- Jana Drozenova,
- Katerina Mojzisova,
- Anna Fialova,
- Sarka Vosahlikova,
- Jan Laco,
- Ales Ryska,
- Pavel Dundr,
- Roman Kocian,
- Tomas Brtnicky,
- Petr Skapa,
- Linda Capkova,
- Marek Kovar,
- Jan Prochazka,
- Ivan Praznovec,
- Vladimir Koblizek,
- Alice Taskova,
- Hisashi Tanaka,
- Robert Lischke,
- Fernando Casas Mendez,
- Jiri Vachtenheim,
- Viola Heinzelmann-Schwarz,
- Francis Jacob,
- Iain A. McNeish,
- Michal J. Halaska,
- Lukas Rob,
- David Cibula,
- Sandra Orsulic,
- Lorenzo Galluzzi,
- Radek Spisek,
- Jitka Fucikova
Affiliations
- Lenka Kasikova
- Sotio Biotech a.s.
- Jana Rakova
- Sotio Biotech a.s.
- Michal Hensler
- Sotio Biotech a.s.
- Tereza Lanickova
- Sotio Biotech a.s.
- Jana Tomankova
- Sotio Biotech a.s.
- Josef Pasulka
- Sotio Biotech a.s.
- Jana Drozenova
- Department of Pathology, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady
- Katerina Mojzisova
- Sotio Biotech a.s.
- Anna Fialova
- Sotio Biotech a.s.
- Sarka Vosahlikova
- Sotio Biotech a.s.
- Jan Laco
- The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove
- Ales Ryska
- The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove
- Pavel Dundr
- Department of Pathology, 1st Faculty of Medicine, Charles University and General University Hospital
- Roman Kocian
- Department of Gynaecology, Obstetrics and Neonatology, General University Hospital in Prague, 1st Faculty of Medicine, Charles University
- Tomas Brtnicky
- Department of Gynecology and Obstetrics, 1st Faculty of Medicine, Charles University, University Hospital Bulovka
- Petr Skapa
- Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol
- Linda Capkova
- Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol
- Marek Kovar
- Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences
- Jan Prochazka
- Czech Center for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences
- Ivan Praznovec
- Department of Gynecology and Obstetrics, Charles University, Faculty of Medicine and University Hospital Hradec Kralove
- Vladimir Koblizek
- Department of Pneumology, University Hospital Hradec Kralove
- Alice Taskova
- Department of Thoracic Surgery, Charles University, 3rd Faculty of Medicine and Thomayer University Hospital
- Hisashi Tanaka
- Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
- Robert Lischke
- 3rd Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol
- Fernando Casas Mendez
- Oncology and Pneumology Department, 2nd Faculty of Medicine, Charles University and University Hospital Motol
- Jiri Vachtenheim
- 3rd Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol
- Viola Heinzelmann-Schwarz
- Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel
- Francis Jacob
- Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel
- Iain A. McNeish
- Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London
- Michal J. Halaska
- Department of Gynecology and Obstetrics, Charles University, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady
- Lukas Rob
- Department of Gynecology and Obstetrics, Charles University, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady
- David Cibula
- Department of Gynaecology, Obstetrics and Neonatology, General University Hospital in Prague, 1st Faculty of Medicine, Charles University
- Sandra Orsulic
- Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles
- Lorenzo Galluzzi
- Department of Radiation Oncology, Weill Cornell Medical College
- Radek Spisek
- Sotio Biotech a.s.
- Jitka Fucikova
- Sotio Biotech a.s.
- DOI
- https://doi.org/10.1038/s41467-024-46873-w
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 19
Abstract
Abstract Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in various cohorts of patients with cancer, reflecting their contribution to the development of tumor-targeting immunity. Here, we demonstrate that high-grade serous ovarian carcinoma (HGSOC) contains distinct immune aggregates with varying degrees of organization and maturation. Specifically, mature TLSs (mTLS) as forming only in 16% of HGSOCs with relatively elevated tumor mutational burden (TMB) are associated with an increased intratumoral density of CD8+ effector T (TEFF) cells and TIM3+PD1+, hence poorly immune checkpoint inhibitor (ICI)-sensitive, CD8+ T cells. Conversely, CD8+ T cells from immunologically hot tumors like non-small cell lung carcinoma (NSCLC) are enriched in ICI-responsive TCF1+ PD1+ T cells. Spatial B-cell profiling identifies patterns of in situ maturation and differentiation associated with mTLSs. Moreover, B-cell depletion promotes signs of a dysfunctional CD8+ T cell compartment among tumor-infiltrating lymphocytes from freshly isolated HGSOC and NSCLC biopsies. Taken together, our data demonstrate that – at odds with NSCLC – HGSOC is associated with a low density of follicular helper T cells and thus develops a limited number of mTLS that might be insufficient to preserve a ICI-sensitive TCF1+PD1+ CD8+ T cell phenotype. These findings point to key quantitative and qualitative differences between mTLSs in ICI-responsive vs ICI-irresponsive neoplasms that may guide the development of alternative immunotherapies for patients with HGSOC.